Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Elsie M Eugui

Anthony C Allison

Peter H Nelson

William A Lee

Chee-Liang L Gu

Paul Parren

Stefan Seeber

Jan Van De Winkel

Aran Frank Labrijn

Ralf Schumacher

Yvo Graus

Martin Lanzendoerfer

Frank Rebers

Martine Van Vugt

Maria Elena Fuentes

Joseph Endl

Joseph M Muchowski

Marvin P Masada

John S Kenney

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Anti-OX40L antibodies

Heterocyclic aminoalkyl esters of mycophenolic acid, and the derivatives and pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, anti-inflammatory agents, anti-tumor agents, anti-viral agents, and anti-psoriatic agents.

Treatment of autoimmune inflammatory, and psoriatic diseases with

The compounds and pharmaceutical compositions of Formula A, wherein Z is hydrogen or --C(O)R, Y is hydrogen or morpholinoethyl, and where R is lower alkyl or aryl, and the pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, particularly for treatment of allograft rejection, especially including cardiac allograft rejection, pancreatic allograft rejection and renal allograft rejection, and for treating autoimmune diabetes. ##STR1##

Treatment of autoimmune diseases with mycophenolic acid, and derivatives

A method of treating rheumatoid arthritis which method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula: ##STR1## and the pharmaceutically acceptable salts thereof, wherein: A is oxygen or sulfur;

Mycophenolic acid derivatives in the treatment of rheumatoid arthritis

The compounds and pharmaceutical compositions of Formula A, wherein Z is hydrogen or --C(O)R, where R is lower alkyl or aryl, and the pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, anti-inflammatory agents, anti-tumor agents, anti-viral agents, and anti-psoriatic agents. ##STR1##

Method of treating diseases by administering morpholino-ethylester of

Treatment of autoimmune diseases with the morpholinoethyl ester of

The present invention is concerned with novel monoclonal antibodies which bind to Interleukin-1.beta. and do not bind to Interleukin-1.beta.. The antibodies bind to Interleukin-1.beta. and block receptor binding and biological activity. The antibodies find use in, for example, diagnostic methods such as an assay for the detection of Interleukin-1.beta..

Growing community of inventors

Belmont, CA, United States of America

Elsie M Eugui